School of Medicine
Showing 11,041-11,060 of 13,033 Results
-
Katherine Sutherland, PA-C
Temporary Employee, Medicine - Med/Blood and Marrow Transplantation
BioKatherine completed her PA degree at Stanford University and worked as a PA in Cutaneous Oncology for 2 years prior to transitioning to Stanford BMT in 2012. Katherine transitioned to part time work in January 2016 and now works on the inpatient service on an as needed basis.
-
Ken Suzuki
Postdoctoral Scholar, General Surgery
BioKen Suzuki is a postdoctoral researcher at Stanford University's Department of Surgery. He received his PhD in Economics from the University of California at Santa Cruz in June 2024. Before UC Santa Cruz, he earned his MA in Economics from Hitotsubashi University in 2017 and his BA in Economics from Yokohama National University in 2015. His research interests include health economics, applied microeconomics, econometrics, and statistical causal inference. His research utilizes large administrative datasets from the Veterans Health Administration (VA) to examine how health policies affect patient healthcare utilization and health outcomes.
-
David Svec, MD, MBA
Clinical Associate Professor, Medicine
Current Research and Scholarly InterestsHigh Value Care: Leading quality improvement projects / research initiatives
-
Katrin J Svensson
Associate Professor of Pathology
Current Research and Scholarly InterestsMolecular metabolism
Protein biochemistry
Cell biology and function
Animal physiology -
James Swartz
James H. Clark Professor in the School of Engineering and Professor of Chemical Engineering and of Bioengineering
Current Research and Scholarly InterestsProgram Overview
The world we enjoy, including the oxygen we breathe, has been beneficially created by biological systems. Consequently, we believe that innovative biotechnologies can also serve to help correct a natural world that non-natural technologies have pushed out of balance. We must work together to provide a sustainable world system capable of equitably improving the lives of over 10 billion people.
Toward that objective, our program focuses on human health as well as planet health. To address particularly difficult challenges, we seek to synergistically combine: 1) the design and evolution of complex protein-based nanoparticles and enzymatic systems with 2) innovative, uniquely capable cell-free production technologies.
To advance human health we focus on: a) achieving the 120 year-old dream of producing “magic bullets”; smart nanoparticles that deliver therapeutics or genetic therapies only to specific cells in our bodies; b) precisely designing and efficiently producing vaccines that mimic viruses to stimulate safe and protective immune responses; and c) providing a rapid point-of-care liquid biopsy that will count and harvest circulating tumor cells.
To address planet health we are pursuing biotechnologies to: a) inexpensively use atmospheric CO2 to produce commodity biochemicals as the basis for a new carbon negative chemical industry, and b) mitigate the intermittency challenges of photovoltaic and wind produced electricity by producing hydrogen either from biomass sugars or directly from sunlight.
More than 25 years ago, Professor Swartz began his pioneering work to develop cell-free biotechnologies. The new ability to precisely focus biological systems toward efficiently addressing new, “non-natural” objectives has proven tremendously useful as we seek to address the crucial and very difficult challenges listed above. Another critical feature of the program is the courage (or naivete) to approach important objectives that require the development and integration of several necessary-but- not-sufficient technology advances. -
Andrew Sweatt
Assistant Professor of Medicine (PACCM)
Current Research and Scholarly InterestsAiming to advance understanding and treatment of pulmonary arterial hypertension (PAH), Dr. Sweatt's research leverages high-throughput molecular profiling, deep clinical phenotypic data, and data science (machine learning and network-based analysis) to identify novel sub-phenotypes and therapeutically-relevant biomarkers in PAH.
